NO982441L - Measurement of drug doses, therapeutics and other glycosaminoglycans (GAGS) - Google Patents

Measurement of drug doses, therapeutics and other glycosaminoglycans (GAGS)

Info

Publication number
NO982441L
NO982441L NO982441A NO982441A NO982441L NO 982441 L NO982441 L NO 982441L NO 982441 A NO982441 A NO 982441A NO 982441 A NO982441 A NO 982441A NO 982441 L NO982441 L NO 982441L
Authority
NO
Norway
Prior art keywords
agent
liver
receptors
bound
treatment
Prior art date
Application number
NO982441A
Other languages
Norwegian (no)
Other versions
NO982441D0 (en
Inventor
Stefan Gustafson
Original Assignee
Hyal Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002164260A external-priority patent/CA2164260C/en
Priority claimed from CA 2173037 external-priority patent/CA2173037A1/en
Application filed by Hyal Pharma Corp filed Critical Hyal Pharma Corp
Publication of NO982441D0 publication Critical patent/NO982441D0/en
Publication of NO982441L publication Critical patent/NO982441L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Fremgangsmåte for behandling av en sykdom eller tilstand i et menneske som kan behandles med en medisin og/eller terapeutisk middel som kan bli transportert av et middel til setet som trenger behandling i kroppen og hvor middelet også kan transportere medisinen og/eller det terapeutiske middelet til leveren (f.eks. binding av transportmiddel til reseptorer på leveren) er tilveiebrakt omfattende: (a) administrering av en effekt ikke-toksisk mengde av et første middel som ikke blir bundet til reseptorer ved setet som trenger behandling, men som bindes med reseptorer av leveren for derved å "ned-regulere" leveren; og (b) deretter administrere en effektiv ikke-toksisk mengde av en medisin og/eller et terapeutisk middel og en effektiv mengde av et andre middel som er et transportmiddel og er et annet middel i forhold til det første middelet som blir bundet til setet som trenger behandling og som har evne til å bli bundet til seter av leveren dersom leveren ikke er blitt "nedregulert" slik at dets bindingskapasitet for det andre middelet er blitt vesentlig redusert av opptaket av leveren av det første middelet administrert under under-paragraf (a) med f.eks. binding med oppfangingsreseptorer til leveren.A method of treating a disease or condition in a human being that can be treated with a drug and / or therapeutic agent that can be transported by an agent to the site in need of treatment in the body and wherein the agent can also transport the medicine and / or therapeutic agent to the liver (e.g., binding of carrier to receptors on the liver) is provided comprising: (a) administering an effect non-toxic amount of a first agent which is not bound to receptors at the site in need of treatment but which binds with receptors of the liver, thereby "down-regulating" the liver; and (b) thereafter administering an effective non-toxic amount of a drug and / or a therapeutic agent and an effective amount of a second agent which is a carrier and is another agent relative to the first agent being bound to the seat which need treatment and which are capable of being bound to sites of the liver if the liver has not been "down-regulated" so that its binding capacity for the second agent has been substantially reduced by the uptake of the liver by the first agent administered under subsection (a) with e.g. binding with capture receptors to the liver.

NO982441A 1995-12-01 1998-05-28 Measurement of drug doses, therapeutics and other glycosaminoglycans (GAGS) NO982441L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA002164260A CA2164260C (en) 1995-12-01 1995-12-01 Targeting of dosages of medicines and therapeutic agents
CA 2173037 CA2173037A1 (en) 1996-03-29 1996-03-29 Targeting of dosages of medicines and therapeutic agents and other glycosaminoglycans (gags)
PCT/CA1996/000793 WO1997020564A1 (en) 1995-12-01 1996-11-29 Targeting of dosages of medicine and therapeutic agents and other glycosaminoglycans (gags)

Publications (2)

Publication Number Publication Date
NO982441D0 NO982441D0 (en) 1998-05-28
NO982441L true NO982441L (en) 1998-05-28

Family

ID=25678243

Family Applications (1)

Application Number Title Priority Date Filing Date
NO982441A NO982441L (en) 1995-12-01 1998-05-28 Measurement of drug doses, therapeutics and other glycosaminoglycans (GAGS)

Country Status (11)

Country Link
EP (1) EP0869798A1 (en)
JP (1) JP2000513707A (en)
KR (1) KR19990071628A (en)
AU (1) AU727001B2 (en)
BR (1) BR9611671A (en)
HU (1) HUP9901935A3 (en)
IL (1) IL124647A0 (en)
MX (1) MX9804343A (en)
NO (1) NO982441L (en)
PL (1) PL326970A1 (en)
WO (1) WO1997020564A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITPD940054A1 (en) * 1994-03-23 1995-09-23 Fidia Advanced Biopolymers Srl SULPHATED POLYSACCHARIDES
ATE376824T1 (en) 1999-01-13 2007-11-15 Alchemia Oncology Pty Ltd USE OF HYALURONAN FOR PRODUCING A MEDICATION TO INCREASE THE EFFECTIVENESS OF CYTOTOXIC DRUGS
AUPQ879500A0 (en) 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US9066919B2 (en) 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
US8937052B2 (en) 2005-07-27 2015-01-20 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
BRPI0615619A2 (en) 2005-09-07 2011-05-24 Alchemia Oncology Pty Ltd therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
AUPM714794A0 (en) * 1994-07-29 1994-08-18 International Fluid Separation Pty Limited Separation apparatus and method
EP0778776A1 (en) * 1994-08-30 1997-06-18 Hyal Pharmaceutical Corporation Hyaluronic acid and derivatives for modulation of cellular activity

Also Published As

Publication number Publication date
IL124647A0 (en) 1998-12-06
HUP9901935A2 (en) 1999-11-29
AU727001B2 (en) 2000-11-30
NO982441D0 (en) 1998-05-28
PL326970A1 (en) 1998-11-09
EP0869798A1 (en) 1998-10-14
HUP9901935A3 (en) 2001-04-28
AU7687896A (en) 1997-06-27
BR9611671A (en) 1999-12-28
KR19990071628A (en) 1999-09-27
JP2000513707A (en) 2000-10-17
MX9804343A (en) 1998-09-30
WO1997020564A1 (en) 1997-06-12

Similar Documents

Publication Publication Date Title
Burnham et al. The effectiveness of topical diclofenac for lateral epicondylitis
Hawi et al. Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus
Fox Acquired salivary dysfunction: drugs and radiation
Garrido et al. Gonyautoxin: new treatment for healing acute and chronic anal fissures
PT751781E (en) USE OF MONOCLONAL ANTIBODIES OR OLIGOMERIC LIGANDS SOLUABLE IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE PREVENTION OR TREATMENT OF NEOPLASTIC DISORDERS
ATE307608T1 (en) COMBINATION OF DOCTAXEL AND RHUMAB HER2 FOR CANCER TREATMENT
IS2630B (en) Treatment of withdrawal symptoms
BRANDRUP Tetrabenacine treatment in persisting dyskinesia caused by psychopharmaca
Straube et al. Studies with cysteinamine and cysteine in x-irradiated animals
NO982441L (en) Measurement of drug doses, therapeutics and other glycosaminoglycans (GAGS)
Ma et al. Blockade of receptor for advanced glycation end-products with azeliragon ameliorates streptozotocin-induced diabetic neuropathy
Lai et al. Combined effect of topical arsenic trioxide and radiation therapy on skin-infiltrating lesions of breast cancer—a pilot study
Langmuir et al. Synergistic interaction between tirapazamine and cyclophosphamide in human breast cancer xenografts
BR9406534A (en) Method for the treatment of neoplastic disease using thiazofurin and ribavirin
MX2022014586A (en) Methods and compositions to treat vascular leak.
SE9903985D0 (en) Use of nitric oxide
Prasad et al. A comparative analysis of the efficacy of topical phenytoin with conventional wound dressing in healing of diabetic foot ulcers
SU1553132A1 (en) Method of treating reactive postinfection arthritis
BR112023025863A2 (en) METHODS TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), TO REDUCE THE FREQUENCY OF MODERATE TO SEVERE EXACERBATIONS IN A PATIENT WITH COPD, TO TREAT OR PREVENT COPD, TO MAINTAIN AND/OR IMPROVE LUNG FUNCTION, TO IMPROVE BASELINE COUNT OF EOSINOPHILS IN THE BLOOD, KIT, ST2 ANTAGONISTS AND ANTI-ST2 ANTIBODY
RU2026069C1 (en) Method of treating costal cartilage dystrophy
CA2164260A1 (en) Targeting of dosages of medicines and therapeutic agents
SU1232257A1 (en) Method of treatment of pulmonary tuberculosis
Weinberg Tipping the scales: biologic therapy 2002
WO2023164277A3 (en) Anti-programmed death-ligand 1 (pd-l1) antibodies
Walling Combination Therapy for Rheumatoid Arthritis